Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Miroslav Boudny"'
Autor:
Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://doaj.org/article/e872ad7d936f40299c20d4bb02b9ef06
Autor:
Stanislav Drápela, Miroslav Boudny, Josef Jaroš, Michaela Špunarová, Jan Verner, Prashant Khirsariya, Zuzana Jašková, Kamil Paruch, Yvona Brychtová, Marie Kasparkova, Jana Zemanová, Jiri Mayer, Marek Borsky, Václav Šeda, Jana Černá, Martin Trbušek, Alexandra Oltová, Marek Mráz, Karel Souček
Publikováno v:
Haematologica
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Autor:
Miroslav Boudny, Martin Trbušek
Publikováno v:
Klinicka Onkologie. 33
Background: Signal transducer and activator of transcription (STAT) proteins are cytoplasmic tran-scription factors that transmit the signal of cytokines, hormones and growth factors. STAT pro-teins control fundamental cellular processes including su
Autor:
Martin Trbušek, Miroslav Boudny
Publikováno v:
Cancer treatment reviews. 88
Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chro
Autor:
Martin Trbušek, PrashantKumar Khirsariya, Yvona Brychtová, Marek Borský, Kamil Paruch, Miroslav Boudny
Publikováno v:
HemaSphere. 3:132
Autor:
Eva Ondroušková, Michaela Bohúnová, Kristýna Závacká, Patrik Čech, Petra Šmuhařová, Miroslav Boudný, Martina Oršulová, Anna Panovská, Lenka Radová, Michael Doubek, Karla Plevová, Marie Jarošová
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of TP53 or ATM, is associated with adverse clinical outcomes. Additional chromosomal abnormalities further stratify patients into groups with diver
Externí odkaz:
https://doaj.org/article/9874afffb5374bcba126ff413f2cbae2